#011 - Hard targets in cancer therapeutics w/ Piers Ingram, CEO & cofounder of Hummingbird Bioscience Asia Healthcare Podcast

In 2015, Piers Ingram co-founded Hummingbird Bioscience, a clinical-stage biotech company in Singapore. Leading a team of interdisciplinary scientists, the company believes that there is a better way to deliver a new generation of transformative medicine: by harnessing powerful modern approaches to systems biology and data science to better understand disease mechanisms and how to treat these, through the development of rationally engineered bio-therapeutics.

Piers joins us to talk about his experience in Asia and starting Hummingbird to develop drugs that go after 'hard targets' in cancer and autoimmune diseases.

Topics we explored:

- How Piers and Jerome met in Shanghai at an alumni event

- Why start Hummingbird Bioscience?

- Why target HER3 and VISTA in cancer drug development?

- How competition and collaboration can both coexist in the biotech industry



Follow Hummingbird Bioscience:

Website – https://hummingbirdbioscience.com/

LinkedIn – https://www.linkedin.com/company/hummingbird-bioscience/



Follow the Asia Healthcare Podcast!

https://anchor.fm/asiahealthcare

Twitter: @jchanpharma

Email: asiahealthcarepodcast@gmail.com



Music used with permission from https://www.jeffcaylor.com/